ex vivo expanded allogeneic γδ T Cells / Emory University - LARVOL DELTA

Aflac-NBL-2002: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Emory University | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Neuroblastoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Aflac-NBL-2002: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Emory University

Combination therapy • Trial completion date • Trial primary completion date • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor

Aflac-NBL-2002: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Aflac-NBL-2002: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Emory University | Trial completion date: Sep 2024 ➔ Dec 2025 | Initiation date: Nov 2022 ➔ Feb 2023 | Trial primary completion date: Sep 2024 ➔ Dec 2025

Combination therapy • Preclinical • Trial completion date • Trial initiation date • Trial primary completion date • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor